Fresenius Kabi said today that it closed its acquisition of Merck KGaA’s biosimilars unit.
The company paid €156 million at closing ($185.7 million USD) and could pay up to €500 million ($595.2 million USD) in milestone payments, which are contingent upon meeting certain drug development targets.
Get the full story at our sister site, Drug Delivery Business News.